Navigation Links
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Date:8/27/2012

cal trials.

- This report deals with different types of endpoint used in respiratory clinical trials. It contains brief account of advantages, disadvantages and regulatory aspects of each type of endpoint.

- This report provides in-depth analysis of clinical trial endpoints used in asthma, COPD, cystic fibrosis and PAH clinical trials.

- This report covers complete account of primary and secondary endpoints used in Phase III and Phase II clinical trials in above mentioned respiratory diseases.

- In this report characterization and segmentation of trials based on their status, along with specific use of endpoints is also provided.

- This report provides profiling of major marketed drugs based on their safety, efficacy and clinical study details.

- The report contains company profiling of major companies associated with marketing of major respiratory drugs covering asthma, COPD, cystic fibrosis and PAH.

- This report also includes endpoint analysis of terminated trials for asthma, COPD, cystic fibrosis and PAH. Analysis of terminated trials can be used in designing more robust trials and avoid any issues, which can result in termination of trial.

Reasons to buy - Understand the pattern of use of primary and secondary endpoints, according to specific indication's and clinical Phase of trial. This will help in designing clinical trials so as to and protect one's product from confronting any of the safety issues.

- To analyze the major primary and secondary endpoint used in disease specific clinical trials.

- Reinforce R&D strategies by identifying new endpoints to be used in disease and clinical phase specific clinical trials. This can increase positive outcome from a trial and aid in bringing molecules with increased efficiency and better safety profiles.

- Develop key strategic initiatives by understanding the key focus of major companies developing drugs in respiratory franchise.

- Buil
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
2. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
5. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
6. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
7. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
9. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
10. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program ... Jones, recently announced that it will be devoting an entire short segment to the ... of people around the globe on a daily basis, but recent advancements in medical ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... 20 grams of high grade protein with zero fat, carbs, sugar, gluten, lactose ... been named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , ...
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:MyGenetx Board Member Receives Veterans Award 2
... illnesses such as diabetes and high blood pressure when ... to a RAND Corporation study issued today. , Even ... new health plan year, a significant number of seniors ... findings published in the September/October edition of the journal ...
... Angeles, Sept. 14, 2007 -- A new study by researchers ... may be good for you. , Researchers found that ... dealt with teen obesity, hypertension and healthy eating habits had ... particularly among men. , The study, published in the Sept. ...
... concern and disappointment about reports that the pending SCHIP ... are critical to access to care for Medicare beneficiaries ... College of Physicians (ACP). David C. Dale, MD, ... the 124,000 internal medicine physicians and medical student members ...
... advance over invasive tests , , FRIDAY, Sept. 21 (HealthDay ... blood could become the lens through which doctors monitor ... study suggests. , "It,s amazing that all these pregnant ... blood," said Dr. Jill L. Maron, the study,s lead ...
... (Nasdaq: ADLS ), has received approval from the ... common stock,to the NASDAQ Capital Market from the NASDAQ ... of the Market today. The Company continues to be,listed ... http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO ) "Advanced Life Sciences currently meets ...
... will honor,Texas House Speaker Tom Craddick and his wife, ... event that sold out faster and well,exceeded the amount ... participants and sponsors still on its waiting list. ... lent their names to,this important event, proceeds from the ...
Cached Medicine News:Health News:Study finds drug spending caps cause some seniors to quit taking key medicines 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Mother's Blood Could Offer Insights Into Fetal Health 2Health News:Mother's Blood Could Offer Insights Into Fetal Health 3Health News:Advanced Life Sciences Joins NASDAQ Capital Market 2Health News:2007 Speaker's Golf Tournament Sets 5-Year Fundraising Record 2
... is a freestanding cryostat with a ... and a radial cutting microtome. It ... wide range of specimens and materials ... in high biohazard risk laboratories where ...
The HM 550 series is a uniquely progressive concept for use with frozen specimens of all types. User applications define module selection and make even serial sectioning enjoyable....
... TP1020 product family are semi-enclosed tissue processors. ... of approved technology with modern and functionally ... safety for tissues at all stages of ... on proven precision mechanics in conjunction with ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
Medicine Products: